Synthesis, molecular docking, and antiproliferative activity studies of bromine bearing Schiff bases
Özet
Bromine-bearing compounds are found in a variety of natural products and synthetic drugs and exhibit a variety of biological activities. They often display particular properties such as enhanced stability, improved lipophilicity, and larger molecular interactions, making them valuable in drug design and development. In this study, three bromine-bearing Schiff bases were synthesized, characterized, and tested in lung (A549) and colon (DLD-1) cancer cell lines for 72 h incubation time. The results demonstrated that compounds had antiproliferative activity in screened cell lines. The compounds were also tested on a healthy embryonic kidney cell line (HEK-293T) to evaluate their toxic effects on non-cancerous cells. In vitro results of compounds interacting with the most suitable target were confirmed by in silico approaches. All bromine-containing compounds were interacted with the receptor tyrosine kinase FLT3 target via molecular docking. From the interaction results of the 6JQR crystal structure with 2-Br, the docking score value was calculated as −8.178 kcal/mol, and this value was determined to be better than the docking score (−7.269 kcal/mol) value of gilteritinib. Pharmacokinetics, toxicity properties and Lipinski violations of the compounds were estimated by ADMET and were calculated to be in the range of recommended values. Molecules demonstrated limited efficacy against A549 cells line, however; they exhibited relatively greater effectiveness against DLD-1 cell line. Notably, the IC50 value of 2-Br was comparable to that of cisplatin. All molecules exhibited minimal toxicity. © 2025 Elsevier Inc.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Karatas, Halis | |
| dc.contributor.author | Turkmenoglu, Burçin | |
| dc.contributor.author | Kokbudak, Zülbiye | |
| dc.contributor.author | Akkoc, Senem | |
| dc.date.accessioned | 2026-10-18T20:26:04.864916424Z | |
| dc.date.available | 2026-10-18T20:26:04.864916424Z | |
| dc.date.issued | 2025 | |
| dc.description.abstract | Bromine-bearing compounds are found in a variety of natural products and synthetic drugs and exhibit a variety of biological activities. They often display particular properties such as enhanced stability, improved lipophilicity, and larger molecular interactions, making them valuable in drug design and development. In this study, three bromine-bearing Schiff bases were synthesized, characterized, and tested in lung (A549) and colon (DLD-1) cancer cell lines for 72 h incubation time. The results demonstrated that compounds had antiproliferative activity in screened cell lines. The compounds were also tested on a healthy embryonic kidney cell line (HEK-293T) to evaluate their toxic effects on non-cancerous cells. In vitro results of compounds interacting with the most suitable target were confirmed by in silico approaches. All bromine-containing compounds were interacted with the receptor tyrosine kinase FLT3 target via molecular docking. From the interaction results of the 6JQR crystal structure with 2-Br, the docking score value was calculated as −8.178 kcal/mol, and this value was determined to be better than the docking score (−7.269 kcal/mol) value of gilteritinib. Pharmacokinetics, toxicity properties and Lipinski violations of the compounds were estimated by ADMET and were calculated to be in the range of recommended values. Molecules demonstrated limited efficacy against A549 cells line, however; they exhibited relatively greater effectiveness against DLD-1 cell line. Notably, the IC50 value of 2-Br was comparable to that of cisplatin. All molecules exhibited minimal toxicity. © 2025 Elsevier Inc. | |
| dc.description.sponsorship | SA gratefully acknowledges the financial support from the S\u00FCleyman Demirel University Research Fund under project number TSG-2024-9516. | |
| dc.identifier.doi | 10.1016/j.bbrc.2025.151739 | |
| dc.identifier.eissn | 1090-2104 | |
| dc.identifier.issn | 0006-291X | |
| dc.identifier.pmid | 40179736 | |
| dc.identifier.scopus | 2-s2.0-105001544504 | |
| dc.identifier.startpage | 151739 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/10969 | |
| dc.identifier.volume | 761 | |
| dc.identifier.wos | WOS:001463159300001 | |
| dc.language.iso | en | |
| dc.publisher | Elsevier B.V. | |
| dc.relation.ispartof | Biochemical and Biophysical Research Communications | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | ADMET | |
| dc.subject | Antiproliferative activity | |
| dc.subject | Bromine | |
| dc.subject | Molecular docking | |
| dc.subject | Schiff base | |
| dc.subject | A549 Cells | |
| dc.subject | Antineoplastic Agents | |
| dc.subject | Cell Line, Tumor | |
| dc.subject | Cell Proliferation | |
| dc.subject | HEK293 Cells | |
| dc.subject | Humans | |
| dc.subject | Molecular Docking Simulation | |
| dc.subject | Schiff Bases | |
| dc.subject | (e) 1 ((2 bromobenzylidene)amino) 5 (4 methoxybenzoyl) 4 (4 methoxyphenyl)pyrimidin 2(1h) one (2 br) | |
| dc.subject | (e) 1 ((3 bromobenzylidene)amino) 5 (4 methoxybenzoyl) 4 (4 methoxyphenyl)pyrimidin 2(1h) one (3 br) | |
| dc.subject | (e) 1 ((4 bromobenzylidene)amino) 5 (4 methoxybenzoyl) 4 (4 methoxyphenyl)pyrimidin 2(1h) one (4 br) | |
| dc.subject | gilteritinib | |
| dc.subject | unclassified drug | |
| dc.subject | antineoplastic agent | |
| dc.subject | admet study | |
| dc.subject | Article | |
| dc.subject | binding site | |
| dc.subject | carbon nuclear magnetic resonance | |
| dc.subject | cell viability | |
| dc.subject | chemical structure | |
| dc.subject | controlled study | |
| dc.subject | crystal structure | |
| dc.subject | cytotoxicity | |
| dc.subject | density functional theory | |
| dc.subject | drug synthesis | |
| dc.title | Synthesis, molecular docking, and antiproliferative activity studies of bromine bearing Schiff bases | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 6 | |
| rdl.citation.wos | 6 | |
| rdl.department | Erzincan Binali Yıldırım University, Faculty of Pharmacy, Department of Analytical Chemistry, Erzincan, 24002, Türkiye. | |
| rdl.oa.status | gold | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |
